Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT01986348 |
Title | Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide |
Acronym | KING |
Recruitment | Terminated |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Karyopharm Therapeutics, Inc |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA | NLD | DNK |